Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning

SINGAPORE, May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Travel goals often begin as ideas scribbled in a notebook or saved Instagram posts but turning them into real experiences can take thoughtful planning. One practical way travellers in Singapore explore these goals is by understanding how Travel Credit Cards can fit into their overall travel checklist. When used mindfully, the right card rewards can help reduce travel-related expenses and make trips feel more achievable. From flights and accommodation to daily spending abroad, a structured approach can help travellers make the most of what they already spend.This checklist is designed to help review travel plans and see how card rewards can support those goals in a realistic, manageable way.Define Your Travel Goals ClearlyClear travel goals provide direction and make planning feel less overwhelming. Instead of a vague plan to "travel more," it helps to identify destinations, timelines, and travel styles. For instance, a short regional trip to Bangkok or Bali may involve different costs and priorities compared to a longer holiday to Europe or Australia. In Singapore, a return flight within Southeast Asia can range between SGD 200 and SGD 500, while long-haul flights may cross SGD 1,200.Understand How Travel Rewards Fit Into Your PlansTravel rewards work best when they match existing spending patterns rather than forcing new habits. Many Travel Credit Cards in Singapore offer reward points or miles on everyday categories, such as dining, online shopping, and transport. Over time, these points can help offset flight bookings or hotel stays. This makes it easier to assess how everyday spending may contribute to future travel plans.Track Your Expenses and Reward PotentialTracking spending is an important part of reviewing how realistic travel goals are. Monthly expenses, such as groceries, utilities, and subscriptions, often total between SGD 1,500 and SGD 2,500 for many households in Singapore. When these expenses are channelled through cards offering travel rewards, points can accumulate gradually. Keeping a simple monthly record can also highlight which categories generate the most rewards.Check Reward Redemption Options and FlexibilityNot all rewards work the same way, so you should review redemption options. Some cards allow points to be converted into airline miles, while others offer travel vouchers or statement credits for travel bookings. Flexibility matters, especially for travellers who prefer multiple airlines or travel dates. Understanding the terms and conditions of rewards also helps clarify what is actually usable for your plans.Review Travel-Related Benefits Beyond RewardsMany Travel Credit Cards come with additional benefits, such as airport lounge access, travel insurance coverage, or discounts on hotel bookings. For example, complimentary lounge access at Changi Airport can help reduce pre-flight expenses, where meals alone may cost SGD 20-40. These features may be useful for travellers who value comfort and convenience alongside rewards.Plan for Overseas Spending and Currency CostsOverseas spending is an important part of any travel checklist, especially when travelling frequently. Foreign currency fees often range between 2.5% and 3.5% per transaction, which can add up quickly on longer trips. Some travel-focused cards offer lower foreign currency fees or bonus rewards for overseas spending. This is worth reviewing before choosing a card for regular use abroad.Review Annual Fees Against Real ValueAnnual fees are an important consideration when reviewing travel-related cards. In Singapore, annual fees for Travel Credit Cards can range from SGD 150 to SGD 500. While higher-fee cards often come with more generous rewards or perks, the value depends on individual travel frequency. A traveller taking one or two trips a year may find sufficient value in mid-range options. Reviewing fee waivers, renewal bonuses, and reward redemption potential can give a clearer picture of overall value.Turning Plans Into Meaningful Travel ExperiencesTravel planning does not have to feel complicated or financially overwhelming. With a clear checklist and realistic expectations, travellers in Singapore can review how everyday spending aligns with their travel goals. Travel Credit Cards, when chosen thoughtfully, can help make trips more accessible by offsetting certain costs and adding convenience. The key lies in understanding rewards, tracking progress, and revisiting goals regularly.Disclaimer: This content is published by iQuanti Singapore Pte. Ltd., an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

雲頂新耀主要股東傅唯再度增持 年內第二次加倉彰顯長期信心

香港, 2026年5月15日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)發佈公告,基於對公司未來前景及長遠發展的堅定信心,公司非執行董事、董事會榮譽主席兼主要股東傅唯先生於2026年5月14日通過公開市場購入公司普通股66萬股,並表示不排除在適當時候進一步增持。本次交易總金額約為2070萬港元,平均價格約為每股31.25港元。這是傅唯2026年以來對雲頂新耀的第二次增持。此前3月27日,他已以每股約38.12港元購入雲頂新耀86萬股股份,總金額約為3270萬港元。主要股東傅唯年內接連增持,充分體現了其對雲頂新耀戰略方向與業績成果的雙重認可。雲頂新耀於2025年底發佈2030年發展戰略,明確以「BD合作+自研」雙輪驅動,目標至2030年營收突破150億元,商業化產品超過20款,持續聚焦腎科、心血管及代謝等藍海領域。2025年12月,管理層及主要股東已通過市場集體增持表達長期信心。業績層面,雲頂新耀2025年全年總收入達人民幣17.07億元,同比增長142%;非國際財務報告准則下首次實現年度盈利,錄得盈利1.87億元,經營性現金流於第四季度成功轉正。核心產品耐賦康®銷售收入達14.43億元,同比增長超300%,成為國內納入醫保首年即超10億元的非腫瘤藥物;依嘉®實現銷售收入2.62億元,院內銷售同比增長44%。這些數據充分驗證了公司商業化能力的持續兌現與不斷增強。從戰略發佈時的管理層集體增持,到2026年內傅唯的兩次獨立加倉,股東及管理層持續以增持行動彰顯對公司前景的信心。在業績兌現與戰略落地的雙重支撐下,雲頂新耀的中長期發展路徑愈發清晰。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

HONG KONG, May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX: 1952.HK) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the company, purchased 660,000 ordinary shares of the company on the open-market for a total consideration of approximately HK$20.7 million, representing an average price of approximately HK$31.25 per Share. Mr. Wei Fu pointed out that he does not rule out the possibility of further increasing his shareholdings in the company when appropriate.This marks Mr. Wei Fu’s second share purchase in Everest Medicines in 2026. Previously, on March 27, he acquired 860,000 shares of Everest Medicines at an average price of approximately HK$38.12 per share, for a total consideration of approximately HK$32.7 million.Mr. Wei Fu’s consecutive share purchases within the year reflect his firm confidence in both Everest Medicines' strategic direction and operational achievements. At the end of 2025, Everest Medicines unveiled its 2030 strategy, which clearly adopts a dual-engine approach driven by both business development collaborations and in-house R&D. By 2030, the company aims to achieve revenue exceeding RMB15 billion and expand its commercialized product portfolio to more than 20 products, while continuing to focus on high-growth therapeutic areas including nephrology, cardiovascular and metabolic diseases. In December 2025, the management team and substantial shareholders collectively increased their shareholdings in the market, signaling long-term confidence in the company’s development.On the operational front, Everest Medicines reported total revenue of RMB1.707 billion for the full year of 2025, representing a year-over-year increase of 142%. The company also achieved annual profitability for the first time on a non-IFRS basis, recording a profit of RMB187 million, while operating cash flow turned positive in the fourth quarter. Sales revenue of NEFECON® reached RMB1.443 billion, representing growth of more than 300% year-over-year, making it the first non-oncology innovative drug in China to exceed RMB1 billion in annual sales in its first year of inclusion in the National Reimbursement Drug List (NRDL). Meanwhile, XERAVA® achieved sales revenue of RMB262 million, with in-hospital sales increasing by 44% year-over-year. These results further validate the company’s strengthening commercialization capabilities and continued execution momentum.The management team’s collective shareholding increases and Mr. Fu’s consecutive share purchases in 2026 demonstrated strong confidence in the Company’s long-term prospects. Supported by strong operational execution and strategic implementation, Everest Medicines’ medium- to long-term growth trajectory is becoming increasingly clear.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Wellgistics Health 透過計劃收購 WellCare Today 及其專屬的 Samsung Galaxy Watch 照護監測計畫,加速其新近宣布的遠端患者監測(RPM)、遠端治療管理(RTM)及慢性病管理(CCM)試點計畫的數位健康擴展

重點摘要:WellCare Today 帶來成熟的 RPM、RTM 和 CCM 基礎設施,並整合穿戴式技術與連網監測解決方案此次整合預計將結合 Wellgistics Health 近期與 Kare Clinicals 共同宣布的 MSO 計畫,以及其涵蓋 6,500 多家獨立藥局的網絡擬議平台旨在提升患者參與度、用藥遵從性、遠程監測及縱向照護協調擬議交易估值約為 1,500 萬美元此戰略計畫旨在為參與的藥局及醫療服務提供者創造額外的臨床營收機會佛羅里達州坦帕市, 2026年5月15日 - (亞太商訊 via SeaPRwire.com) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.(納斯達克代碼:WGRX)(「Wellgistics」或「本公司」)今日宣布,已簽署一份非約束性意向書(「LOI」),擬收購 WellCare Today。擬議的交易結構包括300萬美元的結構化現金付款,餘額將透過以優先股形式發行的績效掛鉤收益支付。WellCare Today 是一家專注於慢性病照護管理(「CCM」)、遠端病患監測(「RPM」)及遠端治療監測(「RTM」)計畫的醫療科技與遠端監測公司。該公司提供 HealthAssist®,這是一套嵌入獨立 Samsung Galaxy Watch 裝置中的先進遠端健康監測平台,作為其更廣泛的「健康監測與緊急支援生態系統」的一部分。該平台透過符合聯邦醫療保險(Medicare)給付資格的 RPM 及 RTM 計畫,實現對心率、血氧濃度、體溫、睡眠模式、活動追蹤以及自報用藥遵從性等關鍵健康指標的被動式持續監測。無法保證任何特定患者、醫療服務提供者、藥房、服務、裝置或工作流程均符合給付資格。根據擬議的交易架構,Wellgistics Health 計劃將 WellCare Today 的 HealthAssist® 平台及其 RPM、RTM 和 CCM 功能,整合至本公司近期宣布的 MSO 試點合作計畫中。該計畫涵蓋 Kare PharmTech, LLC 的子公司 Kare Clinicals,以及其超過 6,500 家獨立藥局的網絡。整合後的基礎設施旨在透過連網穿戴式技術與遠端監測基礎設施,支援跨醫療服務提供者及藥局管道的可擴展性患者參與、用藥遵從性計畫、縱向監測計畫、慢性病管理,以及強化照護協調工作流程。預期此擬議交易亦將為 Wellgistics 藥局網絡內的參與藥局創造機會,使其能參與與 RPM、RTM 及 CCM 計畫相關的臨床服務計畫,同時使醫療服務提供者得以使用可擴展的照護協調、監測及給付基礎設施。雙方認為,此項擬議合作有望透過技術驅動的互動與遠端監測平台,建立一個更緊密連結的醫療保健生態系統,將患者、藥局、醫療服務提供者、穿戴式技術及縱向照護協調服務整合為一。該意向書不具約束力,擬議交易的完成仍須待完成慣例盡職調查、協商並簽署最終協議、取得董事會批准、解決融資考量及其他慣例交割條件後方能確定。無法保證最終協議將得以簽署,亦無法保證擬議交易將如目前所預期完成,或能否完成。關於 Wellgistics Health, Inc.Wellgistics Health(納斯達克代碼:WGRX)是健康資訊科技領域的領導者,將其專有的藥房調劑優化人工智慧平台 EinsteinRx™ 整合至其基於區塊鏈的智慧合約平台 PharmacyChain™,以優化處方藥調劑流程。其整合平台串聯超過 6,500 家藥局及 200 多家製造商,提供批發分銷、數位處方箋傳輸、直接送達患者,以及由人工智慧驅動的樞紐服務,例如資格驗證、新用戶註冊、用藥遵從性支援、事前授權及自費處方箋履行服務,旨在提升處方箋生態系統中患者的用藥可及性與透明度。關於 WellCare Today, LLCWellCare Today 是一家醫療科技公司,提供 HealthAssist® 服務。這是一套先進的遠端健康監測平台,內建於獨立運作的三星 Galaxy Watch 裝置中,作為其全面性「健康監測與緊急支援生態系統」的一部分。HealthAssist® 能夠被動且持續地監測關鍵健康指標,包括每小時心率、每小時血氧濃度、體溫、每日步數、睡眠模式,以及使用者自行回報的用藥遵從性。HealthAssist® 整合了可由聯邦醫療保險(Medicare)給付的遠程治療監測(RTM)及遠程患者監測(RPM)計畫,提供經濟實惠且可擴展的解決方案,旨在協助長者及慢性病患者管理健康狀況。所有 RPM、RTM、CCM 及相關照護協調服務,預期均須由具備適當執照的醫療提供者及參與機構,依照適用的聯邦與州醫療保健法律、聯邦醫療保險(Medicare)及支付方要求、反詐欺與濫用法規、隱私與資料安全要求,以及專業執業規則進行提供、監督、記錄及計費。本公司不透過本新聞稿提供醫療建議,且參與任何計畫均須符合適用的臨床、合約、監管及給付要求。前瞻性陳述本新聞稿包含《1995年私人證券訴訟改革法案》及其他適用聯邦證券法所定義之前瞻性陳述。前瞻性陳述包括但不限於:關於擬收購WellCare Today, LLC之陳述; 任何交易的預期結構、估值、對價、優先股條款及潛在時程;本公司完成盡職調查、協商並簽訂最終協議、取得董事會批准、籌措資金、滿足交割條件並完成擬議交易的能力;WellCare Today的平台、技術、人員、計畫及工作流程與本公司醫療服務組織(MSO)、藥房網絡、醫療服務提供者及醫療保健技術計畫的潛在整合; HealthAssist® 及相關穿戴式技術在遠程患者監測(RPM)、遠程治療管理(RTM)、慢性病管理(CCM)、用藥依從性、患者參與及照護協調計畫中的潛在應用;藥局、醫療服務提供者、患者及支付方的潛在參與;RPM、RTM、CCM 或相關服務的潛在報銷可行性;潛在的營收機會;以及本公司的成長策略、業務計畫與未來表現。前瞻性陳述可透過「可能」、「可能」、「將會」、「應」、「預期」、「預料」、「相信」、「意圖」、「計劃」、「預測」、「估計」、「潛在」、「機會」、「目標」、「預測」、「持續」 「將」及類似表述。此類陳述係基於當前預期、假設及估計,並受各種風險與不確定性影響,其中許多因素超出本公司控制範圍。可能導致實際結果與預期存在重大差異的重要因素包括但不限於:各方未能簽訂最終協議之風險;意向書遭終止或未能促成交易完成之風險; 擬議估值、對價、優先股條款或其他交易條款發生重大變更的風險;未能以可接受條款或完全未能取得所需融資、董事會批准、第三方批准或監管批准的風險;視最終交易條款而定,可能需取得納斯達克股東批准或符合其他納斯達克要求的風險;所收購的技術、計畫或營運未能成功整合的風險; 預期效益、協同效應、醫療服務提供者採用率、藥局參與度、患者參與度、報銷或營收機會未能實現的風險;與醫療保健法規、聯邦醫療保險(Medicare)及支付方要求、詐欺與濫用法規、隱私與資料安全要求、專業執業規則、醫療器材性能、第三方技術依賴性及報銷政策變更相關的風險;以及本公司向美國證券交易委員會(SEC)提交的文件中所描述的其他風險與不確定性。前瞻性陳述僅反映其作出當日的狀況,本公司無義務更新或修訂任何前瞻性陳述,除非適用法律另有規定。Wellgistics 媒體與投資者聯絡資訊媒體: media@wellgisticshealth.com  投資者關係: IR@wellgisticshealth.com  消息來源:Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program

Highlights:WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutionsCombination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmaciesProposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordinationProposed transaction valued at approximately $15 millionStrategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providersTAMPA, FLA., May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million, with the balance to be satisfied through a performance-based earnout issued in preferred stock.WellCare Today is a healthcare technology and remote monitoring company focused on chronic care management ("CCM"), remote patient monitoring ("RPM"), and remote therapeutic monitoring ("RTM") programs. The company delivers HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its broader Health Monitoring & Emergency Support Ecosystem. The platform enables passive, continuous monitoring of key health metrics including heart rate, blood oxygen levels, temperature, sleep patterns, activity tracking, and self-reported medication adherence through Medicare-reimbursable RPM and RTM programs. No assurance can be given that any particular patient, provider, pharmacy, service, device or workflow will qualify for reimbursement.Under the proposed transaction structure, Wellgistics Health intends to integrate WellCare Today's HealthAssist® platform and RPM, RTM and CCM capabilities with the Company's recently announced MSO pilot collaboration involving Kare Clinicals, a division of Kare PharmTech, LLC, as well as its network of more than 6,500 independent pharmacies. The combined infrastructure is intended to support scalable patient engagement, medication adherence initiatives, longitudinal monitoring programs, chronic disease management, and enhanced care coordination workflows across provider and pharmacy channels utilizing connected wearable technologies and remote monitoring infrastructure.The proposed transaction is also expected to create opportunities for participating pharmacies within the Wellgistics Pharmacy Network to engage in clinical service programs associated with RPM, RTM and CCM initiatives, while enabling providers to access scalable care coordination, monitoring, and reimbursement infrastructure. The companies believe the proposed collaboration may establish a more connected healthcare ecosystem aligning patients, pharmacies, providers, wearable technologies, and longitudinal care coordination services through technology-enabled engagement and remote monitoring platforms.The LOI is non-binding, and completion of the proposed transaction remains subject to customary due diligence, negotiation and execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as currently contemplated, or at all.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.About WellCare Today, LLCWellCare Today is a healthcare technology company delivering HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its comprehensive Health Monitoring & Emergency Support Ecosystem. HealthAssist® enables passive, continuous monitoring of key health metrics including hourly heart rate, hourly blood oxygen levels, temperature, daily steps, sleep patterns, and self-reported medication adherence. Integrated with Remote Therapeutic Monitoring (RTM) and Remote Patient Monitoring (RPM) programs reimbursable by Medicare, HealthAssist® delivers an affordable, scalable solution designed to support seniors and individuals managing chronic health conditions.All RPM, RTM, CCM and related care-coordination services are expected to be furnished, supervised, documented and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, and professional practice rules. The Company does not provide medical advice through this press release, and participation in any program will be subject to applicable clinical, contractual, regulatory and reimbursement requirements.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Asset Value Investors (AVI) urges the dismissal of two directors at Wacom

LONDON, May 14, 2026 - (ACN Newswire) - Asset Value Investors Limited (“AVI”) has submitted shareholder proposals on one of AVI Japan Opportunity Trust’s (“AJOT”) portfolio companies, Wacom Corporation (TSE: 6727, “Wacom”) calling for board changes ahead of Wacom’s upcoming Annual General Meeting in June. AVI, Wacom’s largest shareholder on behalf of all the portfolios it manages, is seeking the dismissal of two directors and the appointment of one external director. Alongside these proposals, AVI has disclosed additional material on its Wacom campaign, including a detailed presentation on an updated dedicated website (www.DrawWacomsFuture.com). Since initiating its investment in Wacom in August 2021, AVI has sought various forms of engagement aimed at enhancing the company’s long-term corporate value as Wacom’s largest shareholder. However, the Branded Business, one of Wacom’s principal business segments, fell into loss from FY2023/3 onwards, and business growth has stalled amid the implementation of large-scale restructuring measures. Furthermore, AVI has serious concerns regarding Wacom’s governance framework in light of the recently announced inappropriate acquisition of a company represented by one of Wacom’s own outside directors, despite the absence of tangible business synergies with Wacom, as well as the improper use of corporate resources, including the provision of preferential treatment to the children of the company representative director, Mr Ide. In light of these circumstances, AVI, as the company’s largest shareholder and a long-term investor on behalf of all the portfolios it manages, publicly launched a campaign last year to support sustainable improvements in corporate value. This year, AVI has decided to publish additional materials and submit shareholder proposals at the upcoming annual general meeting, as follows: - Appointment of one outside director - Dismissal of two directors (the Representative Director and one outside director) Kaz Sakai, Head of Japan Research at AVI, commented as follows: “Wacom has demonstrated serious deficiencies in governance oversight. These include the acquisition by Wacom of a loss-making company represented by Mr Nakajima, one of its own external directors, for more than ten million dollars, the subsequent transfer of Mr Nakajima into an internal director role, and conduct by Mr Ide, Wacom’s Representative Director and CEO, that can only reasonably be viewed as a conflation of personal and corporate interests, together with a board that has tolerated such behaviour.” “Wacom must restore the proper functioning of its governance framework without delay. In addition to proposing the dismissal of Mr Ide and Mr Nakajima, whom AVI has concluded are central to these governance failures, AVI has also nominated a candidate for outside director capable of strengthening governance and management. We are confident that, through the board structure recommended by AVI and the implementation of operational improvement measures, Wacom can further reinforce its position as the global market leader in the graphic tablet business.” About Asset Value Investors (AVI): AVI is an investment management company established in London, United Kingdom, in 1985. AVI has invested in Japanese equities for more than 40 years. AVI manages AVI Global Trust (AGT) and AVI Japan Opportunity Trust (AJOT) and other funds, collectively investing Y180bn into the Japanese market. AGT and AJOT are public companies whose shares are listed and traded on the main market of the London Stock Exchange. AVI is a signatory to Japan’s Stewardship Code and is committed to constructive engagement with management teams and boards of its portfolio companies, with the aim of contributing to sustainable growth and enhanced enterprise value. AVI’s holding in Wacom on behalf of all its funds is 13.8% making AVI the largest shareholder (as of 30 April 2026). Wacom is a 5.5% holding in AJOT. Media Contacts: KL Communications, AVI@kl-communications.com +44 (0)20 3882 6644 Ashton Consulting, avijapanpr@ashton.jp This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS Reach: https://www.londonstockexchange.com/news-article/AJOT/avi-urges-the-dismissal-of-two-directors-at-wacom/17592170

Galaxy Payroll Group Limited中期業績顯著改善 經營現金流轉正

香港, 2026年5月14日 - (亞太商訊 via SeaPRwire.com) - Galaxy Payroll Group Limited(納斯達克股票代碼:GLXG)(「GLXG」或「本公司」)是一家薪酬外包及僱傭服務提供商,今日公布其截至2025年12月31日止六個月的未經審計財務業績。財務摘要- 收入增加至1,400萬港元(200萬美元),按年增長約2%;- 客戶總數由196名增加至210名;- 淨虧損由2,650萬港元(340萬美元)大幅改善至110萬港元(10萬美元);- 隨著上一期間非經常性開支恢復正常,經營開支大幅下降;- 經營活動所得現金淨額為125萬港元(20萬美元);- 截至2025年12月31日,現金結餘增加至3,320萬港元(400萬美元)。在跨境僱傭及外包解決方案需求增長的支持下,本公司的僱傭服務業務持續拓展至多個亞洲市場。與上一期間相比,淨虧損大幅減少,主要由於上一財政年度產生的若干一次性研發開支及上市相關成本不再產生。有關截至2025年12月31日止六個月的完整中期未經審計財務報表,請參閱本公司於本新聞稿同日向美國證券交易委員會提交的外國發行人報告。業務更新本公司亦觀察到進入2026年後的業務活動呈現令人鼓舞的跡象,包括部分客戶帳戶的客戶員工人數增加,以及多個市場的項目持續啟動及納入服務流程。但該等觀察屬初步性質,並不能代表未來財務業績。資本狀況截至2025年12月31日,本公司持有現金及現金等價物約3,320萬港元(400萬美元),並擁有營運資金。管理層相信,本公司目前的流動資金狀況足以支持其現行營運計劃及持續業務發展活動。基於目前預期,本公司現時並不預期短期內需要進行外部股本融資,且目前無意於未來12個月內設立「按市價發售」(at-the-market,「ATM」)計劃。該評估仍受市場狀況、業務表現及策略考量影響。管理層評論GLXG行政總裁Frank Lao表示:「我們的中期業績反映,在公開上市後,本公司在穩定並強化營運狀況方面持續取得進展。儘管期內收入增長仍較為平緩,但我們在成本結構及營運表現方面實現了改善。客戶基礎持續擴大、經營現金流轉正,以及進入2026年後業務活動持續推進,均令我們感到鼓舞。我們將繼續專注於嚴謹執行、審慎資本管理,以及為股東創造長期價值。」關於 Galaxy Payroll Group LimitedGalaxy Payroll Group Limited 是一家薪酬外包及僱傭服務提供商,業務覆蓋多個亞洲市場。前瞻性陳述本新聞稿載有適用證券法律所界定的前瞻性陳述。該等陳述乃基於當前預期及假設,並受風險及不確定因素影響,可能導致實際結果出現重大差異。可能導致該等差異的因素包括但不限於市場狀況、客戶需求、競爭環境、監管發展、融資條件,以及本公司執行其業務策略的能力。前瞻性陳述包括有關未來業務活動、增長預期、流動資金及融資意向的陳述。除法律另有要求外,本公司概無義務更新前瞻性陳述。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Galaxy Payroll Group Limited Reports Improved Interim Results and Positive Operating Cash Flow

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - Galaxy Payroll Group Limited (NASDAQ: GLXG) (“GLXG” or the “Company”), a provider of payroll outsourcing and employment services, today announced its unaudited financial results for the six months ended December 31, 2025.Financial Highlights· Revenue increased to HKD14.0 million (US$2.0 million), representing year-over-year growth of approximately 2%· Total number of customers increased from 196 to 210· Net loss improved significantly from HKD26.5 million (US$3.4 million) to HKD1.1 million (US$0.1 million)· Operating expenses declined substantially following normalization of prior-period non-recurring expenses· Net cash provided by operating activities was HKD1.25 million (US$0.2 million)· Cash balance increased to HKD33.2 million (US$4 million) as of December 31, 2025The Company’s employment services business continued to expand across multiple Asian markets, supported by growing demand for cross-border employment and outsourcing solutions.The substantial reduction in net loss compared to the prior period primarily reflected the absence of certain one-time research and development expenditures and listing-related costs incurred during the prior fiscal year.For the full interim unaudited financial statements for the six months ended December 31, 2025, please refer to the report of foreign issuers furnished by the Company with the United States Securities and Exchange Commission on the even day of this release.Business UpdateThe Company has also observed encouraging business activity entering 2026, including increases in client headcount across selected accounts and continued onboarding of projects in multiple markets. These observations are preliminary in nature and may not necessarily be indicative of future financial results.Capital PositionAs of December 31, 2025, the Company maintained cash and cash equivalents of approximately HKD33.2 million (US$4 million) and positive working capital. Management believes the Company’s current liquidity position supports its present operating plan and ongoing business development activities.Based on current expectations, the Company does not currently expect to require near-term external equity financing and has no present intention to establish an at-the-market (“ATM”) offering program over the next 12 months. This assessment remains subject to market conditions, business performance, and strategic considerations.Management CommentaryWai Hong Lao, Chief Executive Officer of GLXG, commented:“Our interim results reflect continued progress in stabilizing and strengthening our operating profile following our public listing. While revenue growth remained modest during the period, we achieved meaningful improvement in our cost structure and operating performance.We are encouraged by the continued expansion of our customer base, positive operating cash flow, and ongoing business activity entering 2026. We remain focused on disciplined execution, prudent capital management, and building long-term shareholder value.”About Galaxy Payroll Group LimitedGalaxy Payroll Group Limited is a provider of payroll outsourcing and employment services operating across multiple Asian markets.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, but are not limited to, market conditions, customer demand, competitive conditions, regulatory developments, financing conditions, and the Company’s ability to execute its business strategy. Forward-looking statements include statements regarding future business activity, growth expectations, liquidity, and financing intentions. The Company undertakes no obligation to update forward-looking statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Euro Manganese Announces Positive Preliminary Economic Assessment

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 14, 2026) - Euro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) and its subsidiary Mangan Chvaletice, s.r.o. ("Mangan" and together the "Company", "Euro Manganese" or "EMN") is pleased to announce the results of a new Preliminary Economic Assessment ("PEA") for the development of its Chvaletice Manganese Project ("Chvaletice Manganese Project", "CMP", or "Project") in the Czech Republic.The PEA is a result of the Company's Optimization Program previously announced1, and builds on the extensive knowledge presented in the Company's Technical Report and Feasibility Study for the Chvaletice Manganese Project, Czech Republic, dated effective July 27, 2022[2], (the "2022 Feasibility Study"). The PEA responds to current market conditions and incorporates the Company's testing campaigns, demonstration plant learnings, and prospective customer testing and feedback to provide an updated preliminary and conceptual development path for the Chvaletice Manganese Project.With most permits secured, a finalized Environmental Impact Assessment ("ESIA"), and official designation as a Strategic Deposit under Czech law and a Strategic Project under the EU Critical Raw Materials Act, Euro Manganese is ready to respond to customers seeking a fully traceable battery-grade manganese supply chain, reducing dependence on Chinese sources and supporting strategic mineral independence objectives.The Chvaletice Manganese Project is well placed to take advantage of U.S. federal procurement and incentive frameworks that increasingly require that critical battery materials — including high-purity manganese used in electric vehicle and energy storage applications — be sourced from allied and US National Defense Act ("NDAA") compliant nations. The Czech Republic, as a NATO member and close U.S. ally, qualifies as an NDAA-compliant source country.HIGHLIGHTS(All economic values are in US dollars unless indicated otherwise)Strong Operating Margin of 48%, demonstrating resilience of the Project and the potential to generate significant returns across commodity price cycles.Robust Returns: Pre-tax IRR of 16.0% and Post-tax IRR of 13.8%, underpinned by a pre-tax NPV of $740M and post-tax NPV of $492M (8% discount rate), showing favorable preliminary economic indicators on historically conservative pricing assumptions.Higher Recoveries, 60% for High-Purity Manganese Sulphate Monohydrate (HPMSM) and 61% for High Purity Manganese Metal (HPEMM), reflecting additional metallurgical test work, operational learnings from the demonstration plant, and process engineering updates.Revised Flowsheet supports 50,000 tpa of HPEMM with full conversion to 150,000 tpa of HPMSM, aligning with battery industry demand while maintaining flexibility to deliver both HPEMM and HPMSM products as customer needs evolve.Newly incorporated magnesium carbonate ("MgCO3") resource as a by-product enables production of up to 20,000 tpa MgCO3, adding incremental value with minimal capital.CAPEX costs remain broadly consistent with the 2022 Feasibility Study, including with increased HPMSM output, despite an inflationary environment.OPEX reduced for per unit cost of HPMSM compared to the 2022 Feasibility Study, due to increased production of HPMSM and updated reagents and energy costs.Updated pricing assumptions demonstrates potential economic viability of the Project even under conservative current market conditions, underscoring its durability through price cycles.Phased development reduces upfront capital requirements, lowers funding risk, and allows further optimization before full-scale expansion.Phase II buildout planned shortly after Phase I commissioning to maximize project value and shareholder returns.Initial Capital, Phase One (50% capacity): $627.5M; Plant Capacity Expansion Capital, Phase Two (to 100% capacity): $197.8M.Annual nominal production: 150,000 tpa HPMSM.Project life: 26 years.Average life of project HPMSM price assumed at $2,888 per tonne.NEXT STEPSThe PEA has enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow.The Company will now advance the Chvaletice Manganese Project further towards a full feasibility study, with a targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies.The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Martina Blahova, President & CEO of Euro Manganese, commented:"The publication of these PEA results marks another important milestone for the Chvaletice Manganese Project. Our recent optimization work has delivered measurable improvements in recovery, confirming both the strength of our technical strategy and the reliability of our process. To enhance capital efficiency and align investment with market demand, we have adopted a phased construction approach that maximizes value while reducing execution risk. The addition of by-product revenue stream further incrementally strengthens the economics of the project."This disciplined approach, coupled with conservative product pricing assumptions, supports a robust project profile with a strong operating margin of 48%, underscoring the Project's ability to perform through market cycles. Despite the challenging market and pricing conditions, the PEA results demonstrate the strength and resilience of the Project. It provides a clear pathway to unlocking the full long-term value of the Chvaletice Manganese Project as demand accelerates for localized, traceable, and sustainably produced battery grade high purity manganese. We are built to perform in volatile markets, engineered for operational efficiency, and positioned to play a strategic role in securing resource independence and reducing vulnerability amid an increasingly complex global landscape."Rick Anthon, Chairman of Euro Manganese, commented:"As a Board, we are encouraged by the progress reflected in this PEA and confident the Chvaletice Manganese Project can deliver on these terms for its shareholders, customers and stakeholders. The team has advanced the Project with a clear focus on technical rigour, capital efficiency, and responsible development. The phased construction strategy and strengthened economic profile demonstrate a thoughtful approach to building a long-life asset that can scale with market demand."With no operating manganese mines in Europe and as the only integrated high purity manganese producer in Europe and North America, the Chvaletice Manganese Project is uniquely positioned to become a cornerstone of Europe's emerging battery materials supply chain. The Project's strategic relevance, combined with its strong environmental credentials and growing commercial traction, reinforces our confidence in its long-term value. We believe the foundations are now firmly in place for Chvaletice Manganese Project to move toward the next stage of development and deliver meaningful returns for shareholders."PEA SUMMARY AND ECONOMIC ANALYSISThe PEA was completed by Tetra Tech Canada Inc. ("Tetra Tech"). A NI 43-101 technical report on the PEA will be filed under the Company's profile on SEDAR+ within 45 days of this news release and made available on the Company's website. A JORC report will be lodged with the Australian Securities Exchange ("ASX") ASX shortly thereafter.The following summarizes the material assumptions used in, and the results of, the PEA, assuming a targeted start of production in 2032.The Czech corporate income tax rate is 21%. In addition to the royalty of CZK 2,308 per tonne of unit Mn produced, the Czech Republic has various payroll and other taxes to generate revenue.The Company has modeled the economics of this project conservatively from a tax perspective, with a full tax burden, based on Czech legislated tax rates.Investment incentives exist in the Czech Republic and the European Union for certain, qualified investments, including investment tax credits, grants, and accelerated depreciation.The Company is actively pursuing these non-dilutive funding opportunities, including investment tax credits, grants, and accelerated depreciation available under both Czech and EU frameworks.Sensitivity AnalysisA sensitivity analysis for the Chvaletice Manganese Project was carried out to determine the effects of key variables in relation to the post-tax NPV of $492 million at a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 below.Initial and Sustaining Capital EstimatesCapital expenditure estimates have been prepared for both initial and sustaining capital. A projected summary timeline of scheduled capital costs is shown in Table 4.The expected initial capital expenditures (Table 4) for the Project, inclusive of capitalized operating startup costs, as estimated by Tetra Tech, as of Q1, 2026, are $627.5 million, including all development-related costs that will be incurred prior to the envisaged commencement of commercial operations. Capital costs incurred after startup are assigned to sustaining capital and are projected to be paid out of operating cash-flows (also see Table 5). Contingencies on initial capital expenditure have been added at appropriate percentages to each component of the Project, excluding capitalized operating costs, resulting in an overall contingency of $66.7 million or 15.5% of direct costs.The Project site is served by excellent existing infrastructure, including rail, highway, a gas pipeline, and water and is adjacent to an operating power plant. The proposed plant site is zoned for industrial use and is the site of the former process plant that produced the Chvaletice tailings.New and refurbished infrastructure that will be built to service the Project include a tailings excavation and handling facility: a south and north site connection utility bridge for transporting tailings slurry, return water pipes and the tube conveyor that returns a mixture of non-magnetic tailings and washed leach residue to the residue dry stacking area; a magnetic separation beneficiation plant; enclosed and winterized process plant buildings and various reagent storage facilities and product warehouse; an upgraded rail spur system with related loading/unloading facilities; an internal road network; an incoming electrical 400kV high voltage grid connection including rectifiers, transformers, GIS switchgear, and local distribution step-down transformers; a process equipment maintenance workshop; a mobile fleet maintenance workshop; spare part and maintenance supply warehouses; a comprehensive water management system, onsite laboratories; and general administrative offices.Operating Cost EstimateOnsite operating costs are expected to average $181.99 per tonne plant feed ($4.14 per kg Mn equivalent) with offsite operating costs estimated to average $31.73 per tonne plant feed ($0.72 per kg Mn equivalent), as shown in Table 5.Resource EstimateTetra Tech was engaged to oversee the planning and execution of sampling and assaying, to prepare the updated Resource Estimate for EMN's Chvaletice Manganese Project, to prepare the Technical Report in accordance with National Instrument 43-101 - Standards and Disclosures for Mineral Projects, and to prepare the independent JORC Code technical report in accordance with the Joint Ore Reserves Committee Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves 2012 Edition ("JORC Code"). The 43-101 Technical Report, entitled "Technical Report and Mineral Resource Estimate for the Chvaletice Manganese Project, Chvaletice, Czech Republic", with an effective date of December 8, 2018 ("the Mineral Resource Estimate"), was filed on SEDAR on January 28, 2019. The corresponding JORC Code technical report with an effective date of December 8, 2018, was lodged on the ASX on February 6, 2019.No additional drilling or data collection pertaining to the technical disclosure of mineral inventory has been undertaken since the completion of the Mineral Resource Estimate, and the effective date for Mineral Resource Estimate is revised to April 27, 2026.The Project's combined Measured and Indicated Resources now amount to 26,960,000 tonnes, grading 7.33% total manganese (tMn) and 5.86% soluble manganese (sMn), as detailed in Table 6 below.PROCESSING FACILITIES DESCRIPTIONTailings Extraction, Residue Storage Facility and ReclamationIn the tailings extraction plan, the three tailings cells will be excavated in a counterclockwise sequence, starting with Cell #3, followed by Cells #1 and #2. Tailings will be extracted using shovel excavators and hauled by truck to an intermediate re-pulping and a covered storage station located between Cells #1 and #2. The storage station will create a 5-day material stockpile. Re-pulped tailings will be fed to the magnetic separation plant via a slurry pipeline on a continuous basis.A filtered blend of non-magnetic tailings and washed leach residue materials from the process plant will be conveyed using a tube conveyor to the storage station and placed and compacted in the Residue Storage Facility (RSF). The excavated area exposed after extraction of the existing tailings will be lined with a geomembrane liner. The RSF will be constructed in stages to suit residue storage requirements and progressively covered to limit the footprint of residue exposed to the air at any given time.RSF design features include a geomembrane lined bottom, perimeter surface water diversion and a contact water collection system that is integrated with the overall site water management system. Dust management includes the implementation of modern dust suppression methods on open faces, interim stack surfaces and haul roads, as required.Progressive reclamation will be undertaken as an integrated part of the residue stacking procedure. The filtered residue cover will consist of a low permeability soil and/or geomembrane cover to inhibit erosion and infiltration, and a growth layer to support vegetation growth.The site is expected to be fully reclaimed and brought back into a productive community to be established in consultation with local communities, regulators and national government agencies. The RSF will be monitored during the post-closure period for geotechnical and environmental performance.High Purity Manganese Products Production FacilityThe processing facilities, including ancillary facilities, for HPMSM production from the CMP tailings were designed by Beijing General Research Institute for Mining ("BGRIMM") together with EMN and Tetra Tech, based on the comprehensive metallurgical test results conducted during the previous PEA and validated through bench scale tests during the feasibility study. Additional metallurgical tests to recover manganese from anode slimes from electrowinning circuit were also conducted to support this PEA.The study was based on the design work completed for the 2022 Feasibility Study which included process circuit and process equipment optimization. Key equipment items were sized and selected based on the FS design by upgrading HPMSM circuit from the nominal capacity of 100,000 t/a to 150,000 t/a. In addition, two additional circuits, one for manganese recovery from anode slimes produced from the electrowinning circuit using reductive leaching and one for sodium and potassium removal from the HPMSM crystallization circuit by incorporating a high-temperature crystallization bypass system. One additional circuit to convert the magnesium carbonate from waste to a saleable by-product is incorporated into the magnesium removal circuit.The CMP process plant has been designed for a nominal nameplate production capacity of 150,000 tonnes per annum of HPMSM by processing approximately 1.1 million tonnes of the historical tailings per year.HPMSM is produced by converting HPEMM flakes produced by electrowinning process without the use of selenium and chromium. This product is expected to best meet the high purity manganese market demand anticipated in current and future battery formulations.The CMP HPMSM product is designed to contain no less than 99.9% high purity manganese sulfate monohydrate and a minimum of 32.34% manganese and will be sold in powder form, produced without the use of fluorine.The dried HPMSM powder product will be packed prior to being shipped in trucks or containers to customers .The process includes following unit circuits:High-intensity wet magnetic separation circuit, upgrading the excavated tailings manganese grade to approximately 15% tMn for acid leaching.Magnetic concentrate sulfuric acid leaching, neutralization to remove impurities and solid-liquid separation.Pregnant leach solution deep purification to further remove heavy metals.Manganese electrowinning to produce high purity HPEMM (high-purity electrolytic manganese metal) flakes using a selenium free process.A magnesium removal process circuit to ensure efficient electrowinning operations and high-quality product and magnesium carbonate produced as a by-product.HPEMM dissolution, solution purification and HPMSM crystallization and drying to produce battery-grade HPMSM for sale.Other supporting circuits, such as ammonium recovery system, water management systems, steam generation. The proposed process flow sheet is illustrated in Figure 1 below.Figure 1: Updated Simplified Process FlowsheetTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11453/297390_4c2a5f3814e549ad_001full.jpgENVIRONMENTAL IMPACTS, PERMITTING AND COMMUNITY ENGAGEMENTEnvironmental impacts are monitored over the long term as part of the project. The ESIA process was conducted in two phases, supplemented by several expert studies and on-site monitoring. The result of the ESIA process, which involved participation from relevant authorities and the public, is the positive Environmental and Social Binding Statement, which was issued by the Ministry of Environment in March 2024. The ESIA permit is a crucial permit demonstrating that the assessed impacts on individual environmental components and the social sphere are acceptable and that the project is feasible.The assessment results show that the implementation of the project will not worsen existing environmental conditions and will not have negative social impacts. Furthermore, the realization of the project will reduce the identified contamination of groundwater and surface water in the tailings and its vicinity, where the source of the pollution is demonstrably deposited material. As the deposit is of anthropogenic origin and the mined material is a waste-product, this constitutes the reuse or recycling of waste, aligning with the principles of the circular economy. The aim of remediation and reclamation is to create a near-natural area with high biodiversity and stability, which will be used for recreational and sports activities.The ESIA process is followed by a subsequent permitting process when a significant portion of the permits had already been obtained, such as the Permit for the location of the processing plant, the Permit for the location of the rail spur, Product registration under the EU's REACH Regulation, and other permits related to auxiliary activities (utility relocations, grid connection, and others). Another key permit is the Determination of the Mining Lease Permit, which was granted to MANGAN Chvaletice, s.r.o on January 23, 2025; this is another crucial permit which authorizes the company to conduct mining activities. In the following steps, the company will undergo the permitting process stipulated by the Building Act, followed by the final operating permit.In 2026, the Company will continue to advance the permitting process under the Building Act, targeting completion of the final operating permit pathway in line with the feasibility study timeline. Each permitting milestone achieved further reduces Project risk and reinforces the Company's readiness to move into the next phase of development.Key Highlights of the Social Commitment:Significant Economic Catalyst: The Project will act as a primary economic driver in the Pardubice Region, creating 800-1,000 jobs during construction and providing stable, long-term employment for approximately 400 direct staff during operations, with a strong 85% local hiring commitment.Commitment to Transparency: The Project has established a robust engagement framework, including a dedicated public information center in Chvaletice and dedicated digital platforms (project-specific website and online grievance tools).Validated Social Acceptance: On March 27, 2024, the Czech Ministry of the Environment issued a favorable binding ESIA opinion, confirming that the Project meets the highest environmental and social standards. The Project currently faces no material barriers to acceptance, reflecting a strong Social License to Operate.BENEFITS OF PEA AND NEXT STEPSThe PEA enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow. The Company plans to explore this and other avenues to advance the Chvaletice Manganese Project further towards feasibility study, with targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies. The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Competent and Qualified Person StatementAll production targets for the Chvaletice Manganese Project referred to in this news release are underpinned by estimated Measured and Indicated Mineral Resources prepared by Competent Persons and Qualified Persons in accordance with the requirements of the JORC Code and NI 43 - 101, respectively. Additionally, the scientific and technical information included in this news release, is based upon information prepared, verified, and approved by Mr. James Barr, P. Geo, Senior Geologist, Mr. Jianhui (John) Huang, Ph.D., P. Eng., Senior Metallurgical Engineer, Mr. Hassan Ghaffari, P.Eng, M.A.Sc., Senior Process Engineer, Mr. Chris Johns, P.Eng, Senior Geotechnical Engineer, and Mrs. Maurie Marks, P.Eng, Senior Mining Engineer, all with Tetra Tech. Mr. Barr, Mrs. Marks, Mr. Ghaffari, Mr. Johns, Mr. Hasanloo and Mr. Huang are consultants to, and independent of, EMN within the meaning of NI 43-101, and have sufficient experience in the field of activity being reported to qualify as Competent Persons as defined in the JORC Code, and are Qualified Persons, as defined in NI 43-101. Mr. Barr is responsible for the Mineral Resource Estimate, Mr. Huang is responsible for the metallurgical test work results, process engineering, operating cost and capital cost estimates, environmental studies, permitting, and social or community impact. Mr. Ghaffari is responsible for infrastructure, Mrs. Marks is responsible for mining and financial analysis, Mr. Johns is responsible for design of the residue storage facility. Mr. Barr visited the property during the 2017 drilling program and again during the 2018 drilling campaign, on July 30-31st, 2018, during which time he observed the drilling, sample collection and preparation, sample logging and sample storage facilities. Mr. Huang visited the Project site on February 5, 2018 and May 3, 2022, as well as visited the Changsha Research Institute of Mining and Metallurgy Co. ("CRIMM") laboratory and pilot plant facility five times between January 20, 2017 and September 20, 2018 to witness sample preparation and test/assay facilities and to discuss the test program and results with CRIMM's technical team. Mr. Huang also visited the SGS Minerals Services (SGS) laboratory on June 29, 2017, and oversaw the bench scale validation test work completed by BGRIMM. Mrs. Marks, Mr. Johns and Mr. Ghaffari also visited the project site on May 3, 2022. Barr, Huang, Ghaffari, Johns and Marks have no economic or financial interest in the Company and consent to the inclusion in this news release of the matters based on their information in the form and context in which it appears.In addition, technical information concerning the Chvaletice Manganese Project is reviewed by Dr. David Dreisinger, P. Eng, a Qualified Person under NI 43-101. Dr. Dreisinger has reviewed and approved the information in this news release for which he is responsible and has consented to the inclusion of the matters in this news release based on the information in the form and context in which it appears.Cautionary StatementThe PEA is a high-level review of potential, is preliminary in nature, and there is no certainty that the economics in the PEA will be realized. The PEA results are not equivalent to, and should not be construed as, a Pre-Feasibility Study or Feasibility Study. Accordingly, investors are reminded that the PEA is considered preliminary in nature and includes estimated costs that are subject to an approximate margin error of plus or minus 35%. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability, and there is no guarantee the Project's resources will eventually be classified as reserves.The projected process plant design, potential production profile and project plan are conceptual in nature and additional technical studies will need to be completed in order to fully assess their viability. There is no certainty that a potential production decision will be made, or that a commercial operation will be achieved.A sensitivity analysis for the Project was carried out to determine the effects of key variables in relation to the post-tax NPV of US$492 million using a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 of this announcement. Additional sensitivities from changes in capital and operating costs, recoveries, and metal prices are also included in Table 3.The PEA is also based on the material assumptions outlined in this announcement. These include assumptions about the availability of funding. While EMN considers all of the material assumptions to be based on reasonable grounds, including those related to funding, there is no certainty that they will prove to be correct or that the range of outcomes indicated by the PEA can be achieved.To achieve the range of outcomes indicated in the PEA, funding in the order of approximately US$670.9 million is assumed to be required for initial capital expenditures and working capital. It is anticipated that funding will be sourced through a combination of equity and debt, and possibly other means; however, given that the PEA is considered preliminary in nature, the Company expects to finalize its financing strategy for the Project in conjunction with, or after, the completion of the feasibility study.Investors should note that there is no certainty that EMN will be able to raise that amount of funding when needed. It is also likely that such funding may only be available on terms that may be dilutive to or otherwise affect the fundamental value of EMN's existing shares. It is also possible that the Company could pursue other 'value realisation' strategies such as a sale, partial sale or joint venture of the Project. If such strategies are pursued, it could materially reduce EMN's proportionate ownership of the Project. Given the uncertainties involved, investors should not make any investment decisions based solely on the results of the PEA.Euro Manganese is dual listed on the TSX-V and the ASX. Neither TSX Venture Exchange nor its Regulation Services Provider (as defined by TSXV policies) or the ASX accepts responsibility for the adequacy or accuracy of this release.Authorized for release by the President and CEO of Euro Manganese Inc.Martina BlahovaPresident and CEO+1 (604) 681-1010info@mn25.caJane Morgan ManagementJane MorganInvestor and Media Relations - Australia+61 (0) 405 555 618jm@janemorganmanagement.com.auLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574neil.weber@loderockadvisors.com  About Euro ManganeseEuro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) is a battery materials company developing the Chvaletice Manganese Project in the Czech Republic, Europe's only near-term source of high-purity manganese, a critical ingredient in next-generation electric vehicles, energy storage batteries and defence applications.The Chvaletice Manganese Project aims to reprocess historic mine tailings to produce high-purity electrolytic manganese metal (HPEMM), and high-purity manganese sulphate monohydrate (HPMSM), establishing a fully traceable, low-carbon supply chain within the European Union.Euro Manganese is positioned to become Europe's first domestic producer of high-purity manganese, meeting the rising demand for sustainable, strategic battery materials while advancing Europe's clean-energy and supply-chain independence goals.Forward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.Forward looking information or statements include all of the results of the PEA, including estimates of internal rates of return (including any pre-tax and after-tax internal rates of return, payback periods, net present values, future production, estimates of cash cost, assumed prices for HPEMM and HPMSM and by-products, proposed extraction plans and methods, operating life estimates, cash flow forecasts, metal recoveries and estimates of capital and operating costs. Forward looking statements also include the possibility for a two-stage construction strategy, and the potential to allow for further optimization of the Project in phase two, with lower upfront capital requirements, and to enhance project economics by aligning investment with cash flow. The Company has based its assumptions and analysis on certain factors that are inherently uncertain, including (i) the adequacy of infrastructure; (ii) the ability to develop adequate processing capacity; (iii) the price of HPEMM and HPMSM and by-products; (iv) the availability of equipment and facilities necessary to complete development; (v) the size of future processing plants and future tailings extraction rates; (vi) the cost of consumables and extraction and processing equipment; (vii) unforeseen technological and engineering problems; (viii) currency fluctuations; (ix) changes in laws or regulations; (x) the availability and productivity of skilled labour; and (xi) the regulation of the mining industry by various governmental agencies.Forward-looking statements also include statements regarding the Company's strategy for its Chvaletice Project, ability to access high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies and sell its products, the ability to complete a feasibility study in 2027, and the Company's ability to navigate current market conditions. In addition, forward-looking statements include statements regarding the Company's next steps including: advancing financing efforts; seeking strategic partners, finalizing product testing, and negotiating offtake agreements with customers; Securing remaining land access; progressing key permits; and pursuing government funding.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company, including that the Chvaletice Project will be developed and operate as planned, the results of the PEA are reliable, that the Company will have sufficient financing to continue operations, and that the Company will be able to meet the conditions of its secured financing. Factors that could cause actual results or events to differ materially from current expectations include, among other things: results from the PEA are not accurate; insufficient working capital; inability to meet the conditions of its secured financing, risks due to granting security, lack of availability of financing for developing and advancing the Chvaletice Project; no available government funding or incentives; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in electric vehicle battery markets and chemistries; risks related to fluctuations in currency exchange rates; and changes in laws or regulations by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2025, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297390 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

馭勢科技赴港招股:全场景L4級自動駕駛龍頭 業績穩步增長賦能多場景自動駕駛落地

香港, 2026年5月14日 - (亞太商訊 via SeaPRwire.com) - 近年來,在政策持續護航、技術快速迭代及市場需求升級的多重驅動下,自動駕駛行業迎來黃金發展週期,持續引領產業變革與升級,成為人工智能與實體經濟深度融合的核心賽道,孕育著巨大的發展機遇。5月12日,自動駕駛行業領先企業馭勢科技(北京)股份有限公司(「馭勢科技」或「公司」,股份代號:1511.HK)正式啟動招股,赴港上市進程邁出關鍵一步,不僅標誌著公司將邁入資本賦能的全新發展階段,更將為L4級自動駕駛行業的商業化落地注入強勁動能。據悉,馭勢科技是大中華區專注於無人化L4級技術的自動駕駛解決方案供應商,公司深耕自動駕駛領域十年,依託自主研發的U-Drive®智能駕駛平台,構建了覆蓋感知、決策、控制全鏈條的核心技術體系,可靈活滿足多場景、高級別的自動駕駛應用需求,築牢技術壁壘。馭勢科技自動駕駛解決方案擁有全場景通用適配能力,已規模化落地各類開放及封閉應用場景,覆蓋機場、廠區、物流、營運及機動車輛等多元領域,同時囊括L2級至L4級全譜系自動駕駛級別,實現技術與應用場景深度融合,場景適配與落地能力行業領先。其中,公司在機場、工業園區等封閉核心賽道穩居行業龍頭地位,依託傳統封閉場景的先發優勢與技術積澱,正穩步向外拓展,加速佈局全域開放場景,構建全維度自動駕駛業務版圖。憑藉深厚的技術積累與精准的市場佈局,馭勢科技建立了穩固的行業地位。根據弗若斯特沙利文的資料,公司於2025年按收益計在大中華區封閉場景中商用車L4級自動駕駛解決方案市場的市場份額達3.1%,彰顯了公司在核心細分領域的絕對領先優勢。全場景深度佈局,築牢行業龍頭地位在機場領域,馭勢科技實現了行業突破性發展。根據弗若斯特沙利文的資料,公司是唯一一家為全球機場提供大型商業營運L4級自動駕駛解決方案的供應商,率先實現機場場景「去安全員」商業化運營。目前,公司已成功在香港國際機場部署無人電動牽引車、無人接駁車和無人巡邏車及相關軟硬件,高效完成無人行李及貨物牽引、旅客接駁、機場巡邏等核心服務,獲得市場高度認可與讚譽。截至最後可行日期,公司已與17個中國機場及3個海外機場展開深度合作,同時公司一直在積極探索與中國及全球4個機場的合作機會,持續鞏固在機場運輸領域的領先地位,充分展現了解決方案及服務的可擴展性及適配性。在廠區領域,馭勢科技聚焦無人化物流痛點,提供端到端無人化物流解決方案,成功實現從室內到室外、從室外到室內對原材料、樣品、零件、半成品及製成品的全流程無人化交付,實現從受控廠區環境向開放道路應用的延伸,為產業物流升級提供了全新路徑。在室內運作方面,公司的無人車無需依賴GPS,通過場景記憶技術實現精准作業;在室外運作方面,無人車可適應多種交通工況及全天候環境,具備極強的環境適應性。根據弗若斯特沙利文的資料,於2025年,公司成為提供可實現室內室外自主運作自動駕駛解決方案的最大L4級自動駕駛解決方案供應商之一,解決方案及服務廣泛覆蓋汽車、化工、光伏及鋰電池製造等多個行業,為各行業客戶降本增效、提升運營安全性提供了有力支撐。除已實現規模化落地的機場及廠區場景外,馭勢科技還通過自動駕駛套件解決方案,將自動駕駛應用場景持續拓展至城市道路、港口、礦山、農場及牧場等多元領域,並將通用技術延伸到乘用車高階智駕,獲得頭部主機廠的持續青睞,逐步構建起全場景自動駕駛生態,為未來發展開闢了更廣闊的空間。技術引領口碑彰顯,業績穩步邁入增長通道依託全棧自研的核心技術、全場景的解決方案及成熟的商業化落地能力,馭勢科技獲得市場廣泛認可,商業化落地成效顯著。截至最後可行日期,公司已為6個國家及地區的249名客戶部署解決方案及服務,其中包括35家《財富》中國及世界500強企業,技術實力、安全管控與品質標準均已達全球頭部客戶要求,並建立完善的數據合規管理體系,客戶群體橫跨多元行業領域,為公司持續發展奠定了堅實的客戶基礎。行業認可度持續提升的同時,馭勢科技斬獲多項重磅榮譽,先後入選福布斯中國最具創新力企業榜、《財富》中國最具社會影響力的創業公司及畢馬威中國領先汽車科技企業50強,亦獲《胡潤百富》評為全球獨角獸企業、《科創板日報》評為科創好公司。尤為值得一提的是,公司於2021年榮獲國家重點專精特新「小巨人」企業稱號,充分彰顯了公司在技術創新與行業影響力方面的突出實力,成為行業創新發展的標杆。得益于行業政策紅利持續釋放、核心技術不斷迭代升級及商業化規模穩步擴大,馭勢科技近年來業績保持穩步增長,展現出强勁的發展韌性與增長潜力。財務數據顯示, 2023年至2025年公司營收從1.61億元增至3.28億元,同期,公司毛利從0.79億元增至1.68億元,2023-2025年複合增長率約42.7%,2022至2025年四年總營收增長超4倍,盈利能力持續提升,彰顯了良好的經營質量。 總體而言,中國AI企業的未來藍海與星辰大海,從來不止局限於國內市場,更在於走向全球、深耕國際舞臺。馭勢科技憑藉硬核產品實力、完備的行業資質認證、成熟嚴苛的質量管理體系,以及完善的數據合規架構與全方位本地化服務體系,已獲得全球行業頂尖客戶的高度認可與深度信賴。未來,隨著赴港上市的穩步推進,公司將借助資本的力量,持續加大技術研發投入,拓展更多應用場景,深化全球市場佈局,推動公司業績增長再上新台階,其長期成長潛力值得市場高度期待。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Assembly 在亞太地區推出 Stagwell Search+,AI 正重塑品牌發現模式

香港, 2026年5月14日 - (亞太商訊 via SeaPRwire.com) - 隨著搜尋日益由人工智慧主導並趨向「零點擊」,品牌需要新的策略來塑造其在答案中的呈現方式,而不僅僅是連結。亞太地區已成為人工智慧搜尋採用的全球領導者,78% 的用戶表示每週都會使用。人工智慧搜尋體驗在用戶造訪網站之前,就日益形塑著品牌的發現與考量。為此,全球全通路媒體代理商 Assembly 今日宣布在亞太地區推出 Stagwell Search+——這套全新系統旨在協助品牌理解並影響其在 AI 驅動搜尋環境中的呈現方式。此次推出標誌著從將搜尋視為獨立管道的思維,轉向根本性的變革。相反地,Stagwell Search+ 運作於涵蓋付費、自有、贏得及分享媒體的完整生態系統中,而 AI 生成的答案將決定品牌的能見度與表現。在亞太地區,這種轉變尤為複雜。該地區的大型語言模型環境高度碎片化,涵蓋多種語言與文化背景,導致品牌能見度不一致。某個品牌在某個模型中可能展現權威形象,卻在另一個模型中完全隱形或被錯誤呈現,這為行銷人員帶來了一種嶄新且難以量化的風險。Stagwell Search+ 由 Assembly 與 emberos 合作開發,搭載業界首個專為 AI 搜尋設計的代理式作業系統。該平台持續監測品牌在各模型與語言中的呈現狀況,並協調及衡量內容、媒體與數位管道中各項行動所帶來的提升效果,以改善品牌能見度。系統並非直接將變更自動化套用至各平台,而是透過 AI 代理來引導人類決策——協助團隊採取精準且具策略性的行動,同時維護品牌體驗的品質與完整性。Stagwell Search+ 目前已整合 OpenAI、Gemini、Perplexity、Grok 及 Anthropic 等全球領先模型,並計劃於今年稍晚新增 DeepSeek 等區域性平台的整合功能。「AI 已經在沒有行銷人員參與的情況下做出品牌決策——而在亞太地區,語言與文化的複雜性更讓這項挑戰加劇,」亞太區體驗與執行副總裁 Yi En Chye 表示。「成功的定義不再僅是排名或點擊率,而是取決於品牌能否在提示詞中佔據一席之地。Stagwell Search+ 賦予品牌所需的洞察力與掌控力,使其能在這個新環境中競爭。」關於 AssemblyAssembly 是一家全球性全通路代理商,專為尋求更現代化品牌建構方法的品牌而設立。在 Stagwell 網絡的支持下,我們匯聚數據、人才與技術,從底層開始(而非自上而下)釋放更聰明、更快速且表現更優異的成果。我們充滿好奇心、善於協作且樂於擁抱變革,是一群深信「體驗越佳,表現越優」的實踐者。我們不認為品牌與績效是二選一的關係,對我們而言,兩者永遠不可或缺。我們標誌中的「+/」符號,即所謂的 ORAD,正是這種思維的象徵。它體現了我們的思考方式、建構模式,以及如何在整個行銷漏斗中創造成果。Assembly 的根基建立在三大核心要素之上:專為此目的打造的 STAGE 體驗引擎、由其驅動的戰略產品——品牌績效規劃(BPP),以及專為速度、深度與現代行銷需求而設計的組織架構。這三者相輔相成,讓我們能夠打造更卓越的品牌體驗,重新定義品牌如何透過數據、科技、媒體、創意與商務來建立連結、互動並實現成長。Assembly在全球44個辦公室擁有超過3,000名專家,提供全漏斗解決方案,協助全球最具雄心的品牌發揮卓越表現。了解更多資訊請造訪 assemblyglobal.com。關於 STAGWELLStagwell 是一家透過人工智慧(AI)革新行銷的全球挑戰者網絡。我們為全球最具雄心的品牌提供大規模的創意成效,將引領文化變革的創意與尖端科技相結合,使行銷的藝術與科學相輔相成。在企業家的領導下,我們遍佈 45 多個國家的專家團隊秉持著共同的目標:為客戶提升成效並改善業務成果。歡迎加入我們:www.stagwellglobal.com 。媒體聯絡Kelvin Lee亞太區行銷總監Kelvin.lee@assemblyglobal.com 消息來源:Assembly Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Assembly Rolls out Stagwell Search+ Across APAC as AI Reshapes Brand Discovery

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - As search becomes increasingly AI-led and zero-click, brands need new strategies to shape how they appear in answers, not just in links. APAC has emerged as a global leader in AI Search adoption, with 78% of users reporting weekly usage. Increasingly, AI Search Experiences shape brand discovery and consideration before users ever visit a website.In response, global omnichannel media agency Assembly today announced the rollout of Stagwell Search+ in APAC - a new system designed to help brands understand and influence how they are represented across AI-driven search environments.The launch marks a fundamental shift away from treating search as a standalone channel. Instead, Stagwell Search+ operates across a full ecosystem of paid, owned, earned, and shared media, where AI-generated answers determine visibility and performance. This shift is especially complex in APAC, where a fragmented landscape of large language models, spanning multiple languages and cultural contexts, creates inconsistent brand visibility. A brand may appear authoritative in one model while remaining invisible or misrepresented in another, introducing a new and largely unmeasured risk for marketers.Built by Assembly in partnership with emberos, Stagwell Search+ is powered by the industry's first agentic operating system for AI search. The platform continuously monitors how brands appear across models and languages and orchestrates & measures the lift from actions across content, media, and digital channels to improve visibility. Rather than automating changes directly into platforms, the system is designed to guide human decision-making with AI agents - helping teams take precise, strategic action while protecting the quality and integrity of brand experiences.Stagwell Search+ is currently integrated with leading global models from OpenAI, Gemini, Perplexity, Grok, and Anthropic with additional integrations across regional platforms such as DeepSeek planned for later this year."AI is already making brand decisions without marketers in the room - and in APAC, that challenge is amplified by language and cultural complexity," said Yi En Chye, VP of Experience and Activation, APAC. "Success is no longer defined by rankings or clicks, but by a brand's ability to secure share of prompt. Stagwell Search+ gives brands the visibility and control they need to compete in this new environment."ABOUT ASSEMBLYAssembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don't see brand and performance as an either/or. For us, it's always both. The + symbol in our logo, known as the ORAD, represents this mindset. It's a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly's foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) - and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world's most ambitious brands perform. Learn more at assemblyglobal.com.ABOUT STAGWELLStagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.MEDIA CONTACTKelvin LeeMarketing Director, APACKelvin.lee@assemblyglobal.comSOURCE: Assembly Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Sherlocq Launches the First AI-Native Regulatory Intelligence Platform for Global Financial Services

NEW YORK, USA AND ABU DHABI, UAE, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Sherlocq, the first AI-native regulatory intelligence platform for global financial services, today announced its public launch. Designed for compliance officers, lawyers, risk professionals, and regulators who operate at the intersection of law, governance, and institutional accountability, Sherlocq delivers regulatory intelligence that is precise, traceable, and usable at institutional scale.The launch marks the emergence of a new category in enterprise AI: regulatory intelligence, a vertical distinct from generic AI assistants, conventional regtech monitoring tools, and document management platforms. Sherlocq has been built from the ground up to meet the security, privacy, and domain standards that regulated institutions require, and which no general-purpose AI platform has been designed to deliver.THE PROBLEMFinancial institutions, law firms, regulators, and consultants collectively spend over $300 billion every year on regulatory compliance. More than ten million professionals carry the weight of that complexity daily, tracking regulatory changes across dozens of jurisdictions, reviewing thousands of documents, and making high-stakes decisions that can determine the fate of institutions and individuals alike.Until now, the tools available have been fundamentally inadequate: monitoring without interpretation, alerts without answers, search without synthesis. Regulatory research has remained a largely manual process for decades. Vertical AI has already demonstrated category-defining value in adjacent domains. Regulatory intelligence represents a larger, more global, and more complex opportunity.Sherlocq changes that.THE PLATFORMAt launch, Sherlocq covers the regulatory output of governments, supervisory authorities, and enforcement bodies across 30+ jurisdictions, including the US, UK, UAE, Singapore, and Hong Kong. It ingests, structures, and indexes this information continuously, so when a compliance officer, lawyer, or risk professional asks a question, Sherlocq returns a precise, sourced, and traceable answer in seconds. Research that previously required hours of manual work across multiple sources is completed in under a minute.The platform launches with three live capabilities:Regulatory Research and Analysis - Multi-jurisdiction research, cross-border regulatory comparison, compliance framework analysis, and obligation mapping across the full spectrum of financial services regulation, covering all major regulated financial centres.Document Intelligence - Structured review, gap assessment, benchmarking, and policy analysis against applicable regulatory standards, available on the native Sherlocq platform.Sanctions Intelligence - Real-time, multi-regime sanctions research across OFAC, OFSI, EU, UAE, and 320+ data sources in a single query, with full source traceability. The first AI-native platform to deliver this level of depth and auditability across multiple sanctions regimes simultaneously.Sherlocq is available on web, iOS, and Android, for individual professionals and enterprise organisations. AI connectors are live for Claude and ChatGPT, enabling regulatory research to be accessed directly within the tools professionals already use. Microsoft Copilot and Google Gemini integrations follow shortly.Sherlocq is certified to ISO 27001 and ISO 27701 standards, meeting the security and data privacy requirements of regulated financial institutions globally.FOUNDER'S STATEMENT"I have spent my career sitting across the table from regulators, leading investigations at the highest levels, and advising institutions in the most consequential moments of their existence. In every one of those engagements, the same problem recurred: brilliant professionals, at world-class institutions, spending most of their time on research and cross-referencing that should have been automated years ago. Not because the technology did not exist. Because no one had built it with the rigour, the domain depth, and the institutional trust that this work demands. That is what we built. Sherlocq is not a general AI tool adapted for compliance. It is the intelligence infrastructure that this industry has always needed and never had," said Bhavin Shah, Founder and Chief Executive Officer, Sherlocq.ABOUT THE FOUNDERBhavin Shah is a globally recognised regulatory and compliance leader with over twenty years of experience advising sovereigns, regulators, boards, and financial institutions across their most complex and politically sensitive challenges. His career spans multi-jurisdiction investigations, AML and financial crime reform, regulatory negotiations, crisis management, and governance advisory across the US, UK, Middle East, and Asia Pacific. He has advised some of the world's most consequential regulatory reform processes and financial institutions at moments of institutional stress, enforcement risk, and strategic transformation.Shah is a World Economic Forum Young Global Leader (2020), a board member of the D2A2 digital assets and AI policy forum, and holds executive education credentials from Harvard Business School and Harvard Kennedy School. He serves as an independent non-executive director on the boards of regulated financial institutions, giving him direct and ongoing insight into the governance, compliance, and regulatory pressures that Sherlocq is designed to address.INDUSTRY VOICES"Regulatory complexity has been accelerating for years and this is only compounding with the recent trends toward fragmentation around the globe. The tools available to compliance professionals have not kept pace. Sherlocq addresses that gap in a way that is substantive, not superficial. What distinguishes this platform is that it has been built with a genuine understanding of how regulated institutions work and what they actually need to be more effective and more efficient. The depth, the traceability, and the institutional-grade approach reflect the kind of rigour that regulators and boards rightly expect. I am proud to support Bhavin and the Sherlocq team as they bring this important product to market," said Bryan Stirewalt, Former Chief Executive, Dubai Financial Services Authority; Former National Bank Examiner, Office of the Comptroller of the Currency; Board Advisor, Sherlocq."Running a banking group across more than 35 markets meant living with regulatory complexity as a daily operational reality. Our teams were talented and diligent but the tools available forced them into a process that was slow, fragmented and heavily manual. Sherlocq solves that problem. It gives compliance and legal professionals the structured multi-jurisdictional intelligence that I would have wanted for my team. This is the platform the industry has always needed,” said Arnold Ekpe, Former Group Chief Executive Officer, Ecobank Group; Board Advisor, Sherlocq.ABOUT SHERLOCQSherlocq Inc. is a US-incorporated AI technology company (Delaware) with principal offices in New York and Abu Dhabi, UAE, and the creator of the first AI-native regulatory intelligence platform purpose-built for global financial services. The company has completed a pre-seed financing round backed by investors across the US, UAE, and Europe. Designed for compliance officers, lawyers, risk professionals, regulators, and governance teams, the platform delivers multi-jurisdiction regulatory research, document intelligence, and sanctions intelligence, with workflow automation and deeper enterprise capabilities on the near-term roadmap. Sherlocq is certified to ISO 27001 and ISO 27701 standards and is available globally on web, iOS, and Android. Financial institutions, law firms, and professional services organisations seeking enterprise access are invited to contact hello@sherlocq.com. sherlocq.com | sherlocq.ai | hello@sherlocq.com MEDIA CONTACTFor media enquiries, interview requests with Bhavin Shah, or access to additional materials including product demonstrations, founder biography, and platform assets:Press contact: press@sherlocq.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Agnete Kirk Kristiansen Appointed Chair of the LEGO Foundation

BILLUND, DENMARK, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At the LEGO Foundation's annual meeting, the Board of Directors elected Agnete Kirk Kristiansen as Chair of the Board. As fourth generation member of the Kirk Kristiansen family, owners of the LEGO Group, she becomes only the fifth Chair of the Foundation since it was founded in 1986.Agnete Kirk Kristiansen has served as Deputy Chair of the LEGO Foundation since 2023 and replaces her brother Thomas Kirk Kristiansen who steps down to assume the position of Deputy Chair. In addition to her role at the LEGO Foundation, Agnete Kirk Kristiansen also serves as Deputy Chair of KIRKBI A/S, the family-owned holding and investment company that owns 75% of the LEGO Group.As ascending Chair, Agnete Kirk Kristiansen highlighted the role of the LEGO Foundation in building a brighter tomorrow for children around the world:I am truly honored to step into the role as Chair of the LEGO Foundation and to continue our important work for children. The foundation holds a very special place in our family and has done so ever since it was established more than 40 years ago. A deep sense of responsibility to make a positive difference for children runs through our family and I strongly believe that every child should have the opportunity to thrive and grow. I am proud to contribute to this mission and help carry it forward.The change in chair takes place the year after Agnete stepped into the role as chair of non-profit foundation Ole Kirk's Fond. With the transition, the fourth generation of the owner family is broadening its engagement and commitment to active ownership.Descending Chair Thomas Kirk Kristiansen said:It has been a privilege to chair the LEGO Foundation for the past 10 years, and I am very happy to now pass on the role to Agnete. She is deeply committed to the LEGO Foundation mission, and I know she will do her utmost to further the cause of securing a childhood for all. During her tenure as Deputy Chair, she has played an integral part in shaping the foundation's current strategy and as she steps into the role as Chair, we further widen the active ownership and engagement from the family across the LEGO ecosystem.Thomas Kirk Kristiansen has served as Chair of the LEGO Foundation since 2016 and in that period the foundation has committed grants of more than DKK 15 billion (EUR 2 billion) through partner organisations across the globe to improve children's outcomes.For 40 years, the LEGO Foundation has been focused on giving back and building a better world for children. We are very mindful of the trust families and communities place in us, and it is not a responsibility we take lightly. Even in the most challenging settings, the foundation can help put a smile on a child's face, lift up learners of all abilities and change life paths. We do so with the utmost sensitivity and responsibility, said Agnete Kirk Kristiansen.In addition to safeguarding the continued development and success of the LEGO Group as part-owner, the LEGO Foundation pursues its philanthropic mission to support initiatives within education, research, and child development through funding of and close collaboration with organisations such as Brac, IRC, UNICEF, Save the Children, Norwegian Refugee Council and others.Further changes to the LEGO Foundation BoardIn addition to Agnete and Thomas Kirk Kristiansen changing roles as Chair and Deputy Chair, the LEGO Foundation Board of Directors at its May meeting also elected as member of the Board Ingrid Stange, who brings a wealth of experience in philanthropy, education and non-profit leadership. Further, both Jørgen Vig Knudstorp, former CEO of the LEGO Group, and El Hadji Amadou Gueye Sy (As), former Secretary-General of the International Federation of Red Cross and Red Crescent Societies, left the Board after 16 and four years of service respectively to the LEGO Foundation.Thomas Kirk Kristiansen thanked the two departing Board members for their long-standing commitment to the foundation:We look very much forward to welcoming Ingrid, who brings highly complementary expertise to the board. At the same time, I thank As for bringing invaluable insights and experience to help shape our work.I would also like to extend my sincerest gratitude to Jørgen for his unwavering dedication to the foundation. During his extensive tenure, Jørgen has been instrumental in defining our vision and strategy while never losing sight of the children we are here to serve.Additionally, Malou Aamund, who has served on the Board since 2021, stepped into the role of Second Deputy Chair of the Foundation.Biography: Agnete Kirk KristiansenLEGO Foundation2026 - Chair of the Board of Directors2023 - 2026 Second Deputy Chair of the Board of DirectorsFrom 2008 Member of the Board of DirectorsKIRKBI A/S2024 - Deputy Chair of the BoardCentre for ADHD+, Aarhus, DenmarkFounderOle Kirk's Fond2025 - Chair of the BoardDegreePsychology, Aarhus University, 2010Additional roles, present and past:Executive Manager, KIRK83 Holding ApSMember of the Advisory Board, RucaRepresentative of the fourth generation of the LEGO owner familyExtensive experience in family-owned companies, long-term stewardship and board workLEGO Foundation Board of DirectorsAgnete Kirk Kristiansen - ChairThomas Kirk Kristiansen - First Deputy ChairMalou Aamund - Second Deputy ChairHilary Pennington - Member of the BoardIngrid Stange - Member of the BoardLEGO Foundation Board of Directors Chairs1986 - 1993: Gotfred Kirk Kristiansen (2nd-generation LEGO owner)1993 - 2000: Bent Skov2000 - 2016: Kjeld Kirk Kristiansen (3rd-generation LEGO owner)2016 - 2026: Thomas Kirk Kristiansen (4th-generation LEGO owner)2026 - Agnete Kirk Kristiansen (4th-generation LEGO owner)About LEGO Fonden:The LEGO Foundation is a Danish corporate foundation entrusted with 25 % ownership of the LEGO Group. The Foundation works with partners around the world to support children's needs and champion the dignity of childhood. Through both philanthropic donations and impact investments the Foundation exists to build the conditions and create the space for every child, everywhere, to thrive and grow. More information about the LEGO Foundation can be found at: https://www.legofoundation.com/Contact information:Mads Hvitved Grandmads.hvitved.grand@legofoundation.comSOURCE: LEGO Fonden Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Wellgistics Health 宣布與 Kare PharmTech 展開醫療服務組織 (MSO) 試點合作,目標鎖定規模達 140 億美元的美國疾病管理 (CCM) 與遠程患者監測 (RPM) 服務市場

重點摘要:· 根據第三方產業報告,隨著醫療服務提供者持續轉向價值導向及居家照護模式,美國遠端病患監測(RPM)市場目前規模已達 140 億美元,預計到 2030 年將成長至約 290 億美元,年複合成長率(CAGR)為 12.6%¹· 透過其醫療服務組織(MSO)基礎設施,於多家醫療機構啟動試點計畫,專注於慢性病管理(CCM)及遠距病患監測(RPM)· 迄今透過此試點基礎設施已產生逾1,500筆理賠,且擴展藍圖目標涵蓋更多醫療服務提供者· Wellgistics 藥局網絡擁有超過6,500家獨立藥局,具備支援患者參與及照護協調計畫的優勢· 參與的藥師預期將獲得新的臨床服務營收機會佛羅里達州坦帕市, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.(納斯達克代碼:WGRX)(以下簡稱「Wellgistics」或「本公司」)今日宣布,將與 Kare PharmTech 及 Kare Clinicals 展開試點合作,整合其醫療服務組織(MSO)基礎設施,以支援參與計畫的醫療機構所提供的慢性病照護管理(CCM)及遠端病患監測(RPM)服務。根據第三方產業報告,隨著醫療服務提供者持續轉向價值導向及居家照護模式,美國 RPM 市場目前規模為 140 億美元,預計到 2030 年將達到約 290 億美元,年複合成長率(CAGR)為 12.6%。¹該試點計畫目前涵蓋多家醫療機構,由 Kare Clinicals MSO 代表參與的醫療機構及提供服務的醫療人員擔任帳務處理機構。此計畫旨在透過可擴展的營運流程及科技驅動的工作流程,支援患者參與、照護協調及縱向監測計畫。所有慢性病管理(CCM)及遠距患者監測(RPM)服務,均預期將由持有適當執照的醫療人員及參與實體,依照適用的聯邦與州醫療保健法律、給付要求及支付方計畫規則提供並進行帳務處理。相關企業表示,試點基礎設施已產生超過 1,500 筆理賠申請,並將作為未來擴展計畫的基礎,目標是逐步涵蓋更多醫療服務提供者。作為合作計畫的一部分,Wellgistics Health 擬運用其超過 6,500 家獨立藥局的網絡,協助識別並支援可能從 CCM 和 RPM 服務中受益的合資格患者。隸屬於 Wellgistics 藥局網絡的參與藥局,亦可能有機會參與與該計畫相關的臨床互動計畫。Wellgistics Health, Inc. 總裁兼執行長 Prashant Patel 表示:「我們相信,藥局互動、醫療提供者連結以及科技驅動的照護協調三者的融合,不僅能顯著改善患者治療成效,同時也能為獨立藥局創造新的經濟機會。透過此次與 Kare PharmTech 的試點合作,我們正建立一套基礎架構,旨在支援慢性病管理及遠程患者監測計畫中可擴展的患者參與模式。」Kare PharmTech 創辦人兼執行長米塔爾·帕內拉(Mital Panera)補充道:「我們一直致力於打造一個營運高效的醫療服務組織(MSO)平台,能夠協助醫療提供者進行照護協調與給付流程管理。透過與 Wellgistics Health 及其藥局網絡合作,我們相信能進一步擴大患者參與度、提升照護連續性,並為未來醫療服務提供者的成長建立可擴展的框架。」雙方指出,隨著擴展計畫持續推進,此試點計畫仍須視營運發展、醫療服務提供者參與度及法規遵循等因素而定。關於 Wellgistics Health, Inc.Wellgistics Health(納斯達克代碼:WGRX)是健康資訊科技領域的領導者,將其專有的藥房調劑優化人工智慧平台 EinsteinRx™ 整合至其獲得專利的區塊鏈智慧合約平台 PharmacyChain™ 中,以優化處方藥調劑流程。其整合平台串聯了 6,500 多家藥局(「Wellgistics 藥局網絡」)及 200 多家製造商,提供批發分銷、數位處方箋傳輸、直接送達患者,以及由人工智慧驅動的樞紐服務,例如資格審核、用藥遵從性管理、新用戶註冊、事前授權,以及依需求提供的自費處方箋履約服務,以優化患者的用藥可及性。Wellgistics 提供端到端的解決方案,旨在為美國獨立藥房恢復處方藥市場的獲取管道、透明度及信任。關於 Kare PharmTech, LLC關於 Kare PharmTech, LLCKare Clinicals 隸屬於 Kare PharmTech, LLC 旗下更廣泛的企業生態系統,該公司由 Kiran Patel 博士掌控。Patel 博士於 1992 年創立了 Medicaid 服務供應商 WellCare,並於 2002 年以 2 億美元的價格將其出售。2007年,帕特爾博士創立了 America's 1st Choice Holdings,並收購了 Freedom Health 和 Optimum Holdings。2017年,他將 America's 1st Choice Holdings 出售給 Anthem, Inc.。帕特爾博士是一位知名慈善家,曾獲《佛羅里達趨勢》雜誌評選為「年度佛羅里達人」。前瞻性陳述本新聞稿包含《1995年私人證券訴訟改革法案》所定義的前瞻性陳述。前瞻性陳述包括有關本公司預期、信念、計劃、目標、意圖、策略、未來事件或表現的陳述,包括關於與 Kare PharmTech 及 Kare Clinicals 進行的試點合作所帶來的潛在效益、可擴展性、擴展、商業化、供應商參與、報銷機會、患者參與計劃、營運能力及未來發展,以及 Wellgistics 藥房網絡在支援 CCM 和 RPM 計劃方面預期所扮演的角色。諸如「預期」、「相信」、「可能」、「期望」、「意圖」、「或許」、「計劃」、「潛在」、「預測」、「尋求」、「應」、「將」等詞彙及類似表述,旨在識別前瞻性陳述。這些前瞻性陳述基於當前的預期與假設,並涉及可能導致實際結果與該等陳述所表達或暗示者存在重大差異的風險與不確定性。此類風險與不確定性包括但不限於:與醫療服務提供者採用與參與相關的風險、報銷結果、患者參與程度、營運執行、試點計畫的可擴展性、監管與醫療保健合規考量、適用法律或報銷政策變更、市場對本公司服務的接受度、競爭因素,以及本公司建立並維持戰略關係及成功實施其商業策略的能力。本新聞稿所述之試點合作屬探索性質,無法保證該計畫將帶來擴大的商業關係、重大營收機會或長期營運成功。有關上述及其他風險的更多資訊,可參閱本公司向美國證券交易委員會提交的文件,包括其中所載的風險因素。除法律規定外,本公司無義務因新資訊、未來事件或其他原因而更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體:media@wellgisticshealth.com投資者關係:IR@wellgisticshealth.com[1] MarketsandMarkets - 美國遠程患者監測市場報告來源:Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

標普簡報-國泰君安國際繼續在集團國際化戰略中發揮關鍵作用

香港, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 近日,標普全球(S&P Global)在其發佈的最新簡報中明確表示,預計國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」、「公司」,股份代號:1788.HK)及其直接控股公司國泰海通金融控股有限公司(「國泰海通金控」)作為母公司國泰海通證券股份有限公司(「國泰海通」)核心子公司,將繼續在集團國際化戰略中發揮關鍵作用。標普全球在簡報中指出,國泰君安國際與母公司在投資銀行及財富管理領域的業務協同效應顯著,進一步強化了其在集團內部的重要性。國際化發展為國泰海通的核心戰略重點之一,國泰君安國際將繼續在集團加強全球佈局的過程中扮演關鍵角色。2025年,國泰君安國際及國泰海通金控分別實現利潤增長284%及85%,分別占國泰海通證券當年淨利潤約3%及8%。這一強勁的財務表現,有力印證了公司對集團整體業務發展的貢獻。標普全球預期,國泰君安國際未來兩年仍將作為集團核心子公司之一,持續獲得母公司支持,其發行人信用評級及「穩定」展望將與母公司保持同步。標普全球認為,公司可獲得母公司穩定、及時的支持,包括在必要時通過國泰海通間接受益於上海政府的資源。這份簡報充分反應了公司的現況及對未來發展的預期。國泰君安國際將堅定不移地配合集團國際化戰略,持續提升自身的專業能力及與集團的業務協同效率,為國泰海通集團成為具備國際競爭力與市場引領力的一流投資銀行作出貢獻。注:本文內容基於標普全球評級於2026年5月5日發佈的獨立觀點檔(Tear Sheet:Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.),該文件不構成評級行動。關於國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO於香港聯合交易所主機板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高質量、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com   Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

S&P Tear Sheet: GTJAI Continues to Play a Key Role in the Group’s International Strategy

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd.  (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com.     Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in  disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in  areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.”  Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product  Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAP發布「自主營運企業」願景

美國佛羅里達州奧蘭多,2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 在 2026 SAP Sapphire 大會上,SAP SE(紐交所代號:SAP)正式發布「自主營運企業(Autonomous Enterprise)」願景,旨在優化全球最核心的業務流程,讓人與 AI 無縫協作,在安全可控的前提下,以更高效率、更具策略性的方式,應對日益增長的全球商業需求。SAP 全球CEO柯睿安(Christian Klein)表示:「對於客戶的關鍵任務流程而言,『差不多對』是遠遠不夠的。透過將 SAP Business AI 平台與 SAP自主型管理套件(Autonomous Suite) 結合,我們把 AI agents 深度嵌入業務流程、數據及治理框架之中,確保其能夠提供準確、合乎規格且安全的結果,從而開拓全新增長機遇,並帶來實質的成本節省與效率提升。」Autonomous Enterprise包含一個統一的 AI 平台,用於構建及治理 AI agents,並為其提供業務脈絡;同時亦包括一個可執行核心業務流程的自主型管理套件,以及重新定義人與企業軟件互動方式的全新用戶體驗。推出 SAP Business AI平台SAP Business AI作為全新的基礎平台,專為構建及部署基於真實業務場景的企業級 AI 而設。SAP Business AI 平台將 SAP Business Technology Platform、SAP Business Data Cloud 及 SAP Business AI 整合於一個統一、受監管的環境中。SAP Business AI 平台的核心為 SAP Knowledge Graph,它就像為 AI agents 提供一張結構化的業務地圖,清晰呈現客戶 SAP 系統環境中的每個業務實體、流程及關聯。Joule Studio 是 SAP 面向企業 AI agents、應用程式及 AI agent 工作流構建的 AI 優先解決方案。開發人員可利用 SAP 提供的安全、可擴展,並專為企業級 AI 優化的託管基礎設施,使用自己偏好的無程式碼、專業程式碼及 AI 開發框架進行開發。跨業務職能及行業中部署SAP Autonomous Suite在此基礎上,SAP 亦進一步推出 SAP Autonomous Suite。讓現有業務應用具備 AI agents 能力,從而端到端自主執行業務流程。該套件於財務、供應鏈、採購、人力資本管理及客戶體驗等範疇,部署超過 50 個按業務領域專屬(Domain-specific)的 Joule Assistants。這些assistants透過協調逾 200 個專門 AI agents,實現端到端流程全自動化。例如,全新的Autonomous Close Assistant可透過自動處理日記賬、對賬及錯誤修正,將財務結賬流程由數星期縮短至數天。此外,SAP 發布了 Industry AI,透過七大行業自主型解決方案,進一步擴展其深厚的行業能力。這些方案不僅可端到端執行完整的行業流程,更內置特定行業專屬業務邏輯、數據模型及規格與監管要求。在本次大會上,SAP 展示了與歐洲能源巨頭RWE的合作成果,利用Industry AI幫助減少其海上風力渦輪機的意外停機時間。借助 SAP 的 Autonomous Asset Management 場景,AI agents 可分析數千宗歷史事故數據,識別最可能的根本原因,並自動生成已預填的工作單,附上合適工具建議及有效的修復方案。設計自主型用戶體驗Joule Work也是今次大會的重點發布之一,重新定義了用戶與 SAP 軟件的互動方式。用戶現在不再需要在各個應用之間切換,或於多個畫面手動輸入資料,而是可以直接與 Joule 互動。只要描述所需的業務成果,Joule 便會協調合適的工作流程、數據及 AI agents 完成任務。Joule Work 不單止是對話工具,更會主動呈現相關業務洞察,並在背景自動處理日常任務,令工作即使在人类未主動操控時亦能持續推進。該方案將支援桌面、流動裝置及語音操作,並可跨 SAP 及非 SAP 系統使用。投資1億歐元 加快客戶邁向自主營運SAP 全面升級了客戶及合作夥伴計劃,加快各類企業轉型邁向 Autonomous Enterprise。為促進落實及採用,SAP設立了一項1億歐元的專屬基金,用於支援合作夥伴協助客戶部署由 SAP 開發的 AI assistants 及 AI agents。該基金亦用於支持合作夥伴基於Joule Studio,在 SAP Business AI 平台上延伸或開發全新合作夥伴 AI agents。SAP 同時升級 RISE with SAP 與 SAP GROW 的方案權益,以促進客戶採用 AI。兩者均可使用 Joule Assistants產品組合;RISE with SAP客戶可於首年內啟用 3 個 Joule assistants,而 SAP GROW 客戶則可於上線後即獲得完整 Joule assistants方案的使用權。至於 SAP S/4HANA 本地部署客戶及 SAP ERP Central Component(SAP ECC)客戶,SAP 亦提供相應支援:客戶只要承諾將現有大部分系統遷移至 SAP Cloud ERP,即可獲得部分 AI 場景的使用權,從而在現有系統環境與雲端目標架構之間實現無縫過渡。此外,SAP 亦推出 agent-led transformation 的轉型工具,可將 ERP 系統遷移工作量減少 35%以上,透過大規模自動化系統分析、代碼修復、配置及測試,加快項目推進,並提升可預測性。此外,SAP 亦宣布全方位拓展策略合作夥伴關係︰- 在平台與套件層面:  - SAP將與Anthropic合作,將Claude基礎模型引入SAP的AI平台,用於支援涵蓋人力資源、採購及供應鏈等場景的 Joule Agentic AI;  - 與Amazon Web Services合作,實現SAP Business Data Cloud與Amazon Athena之間的零複製數據整合;  - 與Google Cloud及Microsoft合作,實現Joule 與外部Agentic AI框架之間的雙向agent-to-agent互操作;  - 與Mistral AI及Cohere合作,在SAP云基礎設施上提供主權模型選項;  - 與n8n合作,在Joule Studio內提供可視化AI工作流程編排能力;  - 與NVIDIA合作,借助其OpenShell為Joule Studio提供安全可靠的運行環境;  - 與Parloa合作,將AI agents引入SAP Service Cloud,使其可在全面存取業務數據與服務流程的基礎上,處理客戶互動。- 在實施層面︰  - SAP將與Palantir及Accenture圍繞複雜數據遷移場景展開合作,並與Conduct合作,推動AI驅動的SAP EPR Cloud遷移。更多內容請參閱《SAP Sappire 2026 創新新聞指南》圖片下載:https://bit.ly/42zNb5h關於SAP作為企業應用和商業AI的全球領導者,SAP位於商業和技術的交匯點。50多年來,企業一直信賴SAP通過整合財務、採購、人力資源、供應鏈和客戶體驗等核心業務營運,來發揮其最佳表現。如需瞭解更多SAP資訊,請瀏覽https://www.sap.com/hk 。如要查詢更多資訊,請聯絡(只限傳媒):縱橫傳訊顧問有限公司(SCC)Andico Tsuiandico.tsui@sprg.com.hk+852 2114 4346 / 6902 3831 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com